Skip to main content
AnthropicNew customer

Anthropic Bets on Life Sciences for Its IPO

What happened

Anthropic collaborated with Lilly, providing Claude Enterprise accounts to 50,000 employees.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Anthropic aims to make life sciences a driving force for its next phase of growth. The group already claims six-figure contracts in the pharmaceutical sector, is deploying a dedicated product, and is equipping itself with a laboratory, all while promoting the contribution of AI to biomedical research. This strategy is part of an IPO filing where biology takes center stage. To date, no AI-designed drug has received FDA approval. Anthropic published survey results in August indicating that 91% of its staff believe a Nobel-level discovery by AI is likely by 2030. In the same survey, 39% of American adults share this perspective for the 2030 deadline. According to Anthropic, nine of the ten largest pharmaceutical companies and eight of the ten largest health companies in the Fortune 500 have each invested at least $100,000 in the company over a recent annual period. The company also cites its collaboration with Lilly, which it describes as a $1.3 trillion-valued company with 50,000 employees who have a Claude Enterprise account. According to Anthropic, over 85% of Lilly's staff actively use the tool. This year, Anthropic established a molecular biology laboratory in the Bay Area and acquired the biotech startup Coefficient Bio for $400 million in stock in April. Additionally, the beta version of the Claude Science product appeared in June. The company is currently looking to...

Keep reading with a free account

The rest of this article, and every signal for Anthropic, is in your free account.

Extracted by Autobound

From the Signal API record
Event
New customer

What this signalsA new customer often means more work to staff, deliver and support.

More new customer signals at other companies

The full record

From the Signal API record

Extraction

Confidence
90%
Detected
Oct 31, 2026
signal_type
news
signal_subtype
signs_new_client

Use this data

Get every new customer signal for Anthropic and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Anthropic this week?”

  2. Send it to your own tools

    The Signal API returns new customer signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/3ae1b210-de61-41b7-1496-4240997416c2 returns this record as JSON. POST /v1/companies/enrich returns every signal for anthropic.com.

{
  "signal_id": "3ae1b210-de61-41b7-1496-4240997416c2",
  "signal_type": "news",
  "signal_subtype": "signs_new_client",
  "detected_at": "2026-10-31T11:05:02+00:00",
  "company": {
    "name": "Anthropic",
    "domain": "anthropic.com"
  },
  "data": {
    "url": "https://www.briefia.fr/en/article/anthropic-bets-on-life-sciences-for-its-ipo",
    "title": "Anthropic Bets on Life Sciences for Its IPO - Brief IA",
    "excerpt": "Anthropic aims to make life sciences a driving force for its next phase of growth. The group already claims six-figure contracts in the pharmaceutical sector, is deploying a dedicated product, and is equipping itself with a laboratory, all while promoting the contribution of AI to biomedical research. This strategy is part of an IPO filing where biology takes center stage. To date, no AI-designed drug has received FDA approval. Anthropic published survey results in August indicating that 91% of its staff believe a Nobel-level discovery by AI is likely by 2030. In the same survey, 39% of American adults share this perspective for the 2030 deadline. According to Anthropic, nine of the ten largest pharmaceutical companies and eight of the ten largest health companies in the Fortune 500 have each invested at least $100,000 in the company over a recent annual period. The company also cites its collaboration with Lilly, which it describes as a $1.3 trillion-valued company with 50,000 employees who have a Claude Enterprise account. According to Anthropic, over 85% of Lilly's staff actively use the tool. This year, Anthropic established a molecular biology laboratory in the Bay Area and acquired the biotech startup Coefficient Bio for $400 million in stock in April. Additionally, the beta version of the Claude Science product appeared in June. The company is currently looking to...",
    "summary": "Anthropic collaborated with Lilly, providing Claude Enterprise accounts to 50,000 employees.",
    "planning": false,
    "image_url": "https://uknohvstpdmdzjugegft.supabase.co/storage/v1/object/public/article-images/articles/anthropic-mise-sur-les-sciences-de-la-vie-pour-son-ipo.jpg",
    "confidence": 0.9,
    "published_at": "2026-10-31T11:05:02Z",
    "article_sentence": "The company also cites its collaboration with Lilly, which it describes as a $1.3 trillion-valued company with 50,000 employees who have a Claude Enterprise account.",
    "related_company_name": "Eli Lilly and Company",
    "related_company_domain": "lilly.com"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.